ASBP Overview

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. The Company is a developer of multi-faceted patent-pending drug delivery technology. It is engaged in developing and marketing the disruptive technology for novel sublingual delivery mechanisms for known drugs. Its patent pending delivery system includes components formulated to allow sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract. Its delivery technology is focused on different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. Its Sublingual Aspirin Product addresses cardiology emergencies and pain management. Its other products include Melatonin, Vitamins, Erectile Dysfunction Medication, Caffeine Products, and Other Products, which includes anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide.

Wall Street analysts forecast ASBP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASBP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aspire Biopharma Holdings Inc revenue for the last quarter amounts to 28.35K USD, decreased

Aspire Biopharma Holdings Inc. EPS for the last quarter amounts to -20.57 USD, decreased -95.93

Aspire Biopharma Holdings Inc (ASBP) has 0 emplpoyees as of May 31 2026.

Today ASBP has the market capitalization of 7.11M USD.